AssetMark Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.7M | Sell |
14,207
-1,826
| -11% | -$621K | 0.01% | 677 |
|
|
2025
Q4 | $6.38M | Buy |
16,033
+4,115
| +35% | +$1.82M | 0.01% | 608 |
|
|
2025
Q3 | $5.43M | Buy |
11,918
+375
| +3% | +$153K | 0.01% | 610 |
|
|
2025
Q2 | $3.76M | Buy |
11,543
+902
| +8% | +$250K | 0.01% | 649 |
|
|
2025
Q1 | $2.87M | Buy |
10,641
+608
| +6% | +$156K | 0.01% | 634 |
|
|
2024
Q4 | $2.36M | Buy |
10,033
+847
| +9% | +$223K | 0.01% | 671 |
|
|
2024
Q3 | $2.53M | Buy |
9,186
+700
| +8% | +$182K | 0.01% | 602 |
|
|
2024
Q2 | $2.06M | Buy |
8,486
+905
| +12% | +$143K | 0.01% | 610 |
|
|
2024
Q1 | $1.13M | Buy |
7,581
+668
| +10% | +$111K | ﹤0.01% | 699 |
|
|
2023
Q4 | $1.32M | Buy |
6,913
+1,135
| +20% | +$193K | ﹤0.01% | 612 |
|
|
2023
Q3 | $1.02M | Buy |
5,778
+934
| +19% | +$178K | ﹤0.01% | 610 |
|
|
2023
Q2 | $920K | Buy |
4,844
+475
| +11% | +$94.2K | ﹤0.01% | 629 |
|
|
2023
Q1 | $875K | Buy |
4,369
+306
| +8% | +$64.3K | ﹤0.01% | 624 |
|
|
2022
Q4 | $966K | Buy |
4,063
+1,271
| +46% | +$271K | ﹤0.01% | 588 |
|
|
2022
Q3 | $559K | Buy |
+2,792
| New | +$533K | ﹤0.01% | 635 |
|
|
2020
Q1 | – | Sell |
-96
| Closed | -$11K | – | 1349 |
|
|
2019
Q4 | $11K | Hold |
96
| – | – | ﹤0.01% | 1008 |
|
|
2019
Q3 | $8K | Hold |
96
| – | – | ﹤0.01% | 992 |
|
|
2019
Q2 | $7K | Sell |
96
-45
| -32% | -$3.45K | ﹤0.01% | 1006 |
|
|
2019
Q1 | $13K | Hold |
141
| – | – | ﹤0.01% | 944 |
|
|
2018
Q4 | $10K | Buy |
+141
| New | +$10.8K | ﹤0.01% | 1008 |
|
|
2018
Q1 | – | Sell |
-14
| Closed | -$2K | – | 1413 |
|
|
2017
Q4 | $2K | Buy |
14
+11
| +367% | +$1.38K | ﹤0.01% | 1415 |
|
|
2017
Q3 | $0 | Buy |
+3
| New | +$256 | ﹤0.01% | 1464 |
|
Other funds holding ALNY
VPM
VCM
